Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
Morgan JE. Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review. Clin Exp Ophthalmol 2012;40(4):364–368. DOI: 10.1111/j.1442-9071.2012.02789.x
Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 2017;355(6326):756–760. DOI: 10.1126/science.aal0092
Tribble JR, Vasalauskaite A, Redmond T, et al. Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma. Brain Commun 2019;1(1):fcz035. DOI: 10.1093/braincomms/fcz035
Kouassi Nzoughet J, Chao de la Barca JM, Guehlouz K, et al. Nicotinamide deficiency in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2019;60(7):2509–2514. DOI: 10.1167/iovs.19-27099
Tribble JR, Otmani A, Sun S, et al. Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol 2021;43:101988. DOI: 10.1016/j.redox.2021.101988
Liebmann JM, Cioffi GA. Nicking glaucoma with nicotinamide? N Engl J Med 2017;376(21):2079–2081. DOI: 10.1056/NEJMcibr1702486
Verdin E. NAD in aging, metabolism, and neurodegeneration+. Science 2015;350(6265):1208–1213. DOI: 10.1126/science.aac4854
Williams PA, Harder JM, Foxworth NE, et al. Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma. Front Neurosci 2017;11:232. DOI: 10.3389/fnins.2017.00232
Van Bergen NJ, Crowston JG, Craig JE, et al. Measurement of systemic mitochondrial function in advanced primary open-angle glaucoma and Leber hereditary optic neuropathy. PLoS One 2015;10(10):e0140919. DOI: 10.1371/journal.pone.0140919
Taechameekietichai T, Chansangpetch S, Peerawaranun P, et al. Association between daily niacin intake and glaucoma: national health and nutrition examination survey. Nutrients 2021;13(12):4263. DOI: 10.3390/nu13124263
Williams PA, Harder JM, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma 2017;26(12):1161–1168. DOI: 10.1097/IJG.0000000000000767
Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol 2020;48(7):903–914. DOI: 10.1111/ceo.13818
De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol 2022;140(1):11–18. DOI: 10.1001/jamaophthalmol.2021.4576
Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000;43(11):1337–1345. DOI: 10.1007/s001250051536
Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973;289(22):1180–1182. DOI: 10.1056/NEJM197311292892208
Tittler EH, de Barros DS, Navarro JB, et al. Oral niacin can increase intraocular pressure. Ophthalmic Surg Lasers Imaging 2008;39(4):341–342. DOI: 10.3928/15428877-20080701-17
Barakat MR, Metelitsina TI, DuPont JC, et al. Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. Curr Eye Res 2006;31(7–8):629–634. DOI: 10.1080/02713680600760501
Williams PA, Harder JM, Cardozo BH, et al. Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun Integr Biol 2018;11(1):e1356956. DOI: 10.1080/19420889.2017.1356956
Domanico D, Verboschi F, Altimari S, et al. Ocular effects of niacin: a review of the literature. Med Hypothesis Discov Innov Ophthalmol 2015;4(2):64–71. PMID: 26060832; PMCID: PMC4458328.
Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016;7:12948. DOI: 10.1038/ncomms12948
Araie M, Mayama C. Use of calcium channel blockers for glaucoma. Prog Retin Eye Res 2011;30(1):54–71. DOI: 10.1016/j.preteyeres.2010.09.002
Rosenthal R, Fromm M. Endothelin antagonism as an active principle for glaucoma therapy. Br J Pharmacol 2011;162(4):806–816. DOI: 10.1111/j.1476-5381.2010.01103.x
Mokudai T, Ayoub IA, Sakakibara Y, et al. Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. Stroke 2000;31(7):1679–1685. DOI: 10.1161/01.str.31.7.1679
Cantó C, Houtkooper RH, Pirinen E, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012 15(6):838–847. DOI: 10.1016/j.cmet.2012.04.022
Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013;154(2):430–441. DOI: 10.1016/j.cell.2013.06.016
Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun 2016;7:13103. DOI: 10.1038/ncomms13103
https://clinicaltrials.gov/ct2/show/NCT05275738 accessed on 6th December, 2022
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05968-1 accessed on 6th December, 2022.
https://clinicaltrials.gov/ct2/show/NCT05405868 accessed on 6th December, 2022.